Mayor Mitch Landrieu says it's time for white Southerners to confront their region's past.
Guest Host: John Donvan
When a patient has run out of options, should new options be put on the table?
The U.S. Senate said Yes to that question this month by approving so-called right-to-try legislation, which lets patients request drugs and treatments that are still in clinical trials and haven’t yet been approved for the market.
More than half of U.S. states have passed similar legislation, despite some concerns that patients could be exploited by the companies behind the previously unavailable treatments.
Is this a risk for patients seeking any sign of hope, or another step toward letting Americans control how they handle their lives … and deaths?
- Starlee Coleman Vice President of Communications for the Goldwater Institute
- Sarah Karlin-Smith Healthcare reporter, Politico
- Ameet Sarpatwari Assistant Director of the Program on Regulation Therapeutics and the Law at Brigham and Women’s Hospital and Harvard Medical School
- David Farber Partner in the FDA and Life Sciences Practice at the law firm of King and Spalding
Most Recent Shows
Lawmakers want to know what really happened with Facebook and Cambridge Analytica in 2016, but they may be too late.
We got ourselves into this, and some researchers have a plan for getting ourselves out.
It was an easy bet. Russian President Vladimir Putin was expected to handily secure re-election in a vote Sunday. As [*The Guardian* reports](https://www.com/world/2018/mar/18/vladimir-putin-wins-russian-election-with-more-than-70-of-vote-exit-poll): Turnout, which was seen as a measure…